Business
FDA panel knocks down Pfizer, Lilly’s osteoarthritis pain drug in near-unanimous vote – FierceBiotech
After dozens of trials over more than 15 years, Pfizer and Eli Lilly’s osteoarthritis hopeful was poised for an FDA decision in December 2020—that is, until the…
After dozens of trials over more than 15 years, Pfizer and Eli Lillys osteoarthritis hopeful was poised for an FDA decision in December 2020that is, until the agency called a panel of outside experts to chew over the drugs application. That panel came down against the drug in a vote on Thursday because of major safety risks and an inadequate plan to manage them.
The Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 19-1 that a drug safety strategy proposed…
-
General14 hours agoCoroner to examine treatment of woman who died three days after surgery performed by former Queensland premier’s partner
-
General15 hours agoToo skewed, too gentlemanly | The Spectator Australia
-
General17 hours agoAlbanese beats drum on economy as trade clouds gather
-
Noosa News16 hours agoSurgeon partner of former premier to testify over his patient’s death